OTCPicks.com’s Daily Small Cap and Microcap Newsletter presents a range of the hottest small cap stocks on trading on the OTC and OTCBB markets. In addition to our Newsletters, OTCPicks.com is quickly becoming the premier community destination for small cap and microcap traders to meet up and discuss their top stock picks. Visit http://www.otcpicks.com/microcap.htm today to join this growing community.
Our Stocks to Watch tomorrow include Clacendix Inc. (OTCBB: IONN) and Ingen Technologies Inc. (OTC: IGNT). Visit http://www.otcpicks.com/microcap.htm to register for our Daily Market Mover's Digest Newsletter, and Email Stock Watch Alerts.
ION NETWORKS INCORPORATED (OTCBB: IONN) "Up 375.00% on Friday" Detailed Quote: http://www.otcpicks.com/quotes/IONN.php HealthWarehouse.com, Inc. is a licensed U.S. online mail-order pharmacy based in Cincinnati, Ohio. HealthWarehouse.com is the first company to offer FDA-approved generic prescriptions at $3.50 for 30-day supplies and $9.50 for 90-day supplies with 100% free shipping. HealthWarehouse.com's mission is to redefine the meaning of healthcare and relentlessly strive to make it affordable for all Americans.
IONN News: May 15 - HealthWarehouse.com, Inc. Announces Completion of Business Combination With Clacendix, Inc. Business combination should enable HealthWarehouse.com to accelerate expansion of industry-leading $3.50 prescription drug program HealthWarehouse.com, Inc., a privately held Delaware corporation, and Clacendix, Inc. (OTCBB: IONN) announced the completion of their business combination pursuant to a securities exchange agreement.
The combined company will assume and execute the HealthWarehouse.com business plan as its sole business. In connection with the business combination, Clacendix intends to change its name to HealthWarehouse.com. Until the name change becomes effective, Clacendix shares will continue to be quoted on the OTC Bulletin Board under the ticker IONN.OB. Under the securities exchange agreement, Clacendix acquired all the outstanding capital stock of HealthWarehouse.com from the existing stockholders of HealthWarehouse.com in exchange for newly-issued shares of Clacendix common stock. As a result of the share exchange, HealthWarehouse.com is now a wholly-owned subsidiary of Clacendix and the former HealthWarehouse.com stockholders will own, on a post-transaction basis, approximately 82.4% of the outstanding common stock of Clacendix. Prior to the close of the business combination, HealthWarehouse.com completed a financing, raising net proceeds of $1.2 million from accredited investors. Clacendix will file a Form 8-K on or before May 20, 2009, which will contain detailed business and financial information concerning the combined company. HealthWarehouse.com, a licensed U.S. online mail-order pharmacy, is working to revolutionize the way Americans purchase prescription drugs and healthcare products. In addition to offering cost savings, HealthWarehouse.com seeks to enhance the consumer experience by providing exceptional customer service, convenience and privacy. With some of the lowest priced prescriptions in the United States, 100% free shipping and 90-day returns with no restocking fees, consumers have responded by making HealthWarehouse.com one of the fastest growing online pharmacies. Clacendix CEO, Norman Corn said, "We are truly excited, having searched for a suitable business combination candidate for over a year. HealthWarehouse.com is growing at an incredible rate with an impressive business model that we believe delivers outstanding consumer value." Upon the close of the business combination, the company appointed Lalit Dhadphale as Chairman, President and CEO, in addition to his duties as a director of HealthWarehouse.com, he will now serve as director of the combined company. Patrick E. Delaney, Chief Financial Officer at Clacendix, will continue in the same role. "This is a significant step forward for our company," states CEO Lalit Dhadphale. "We are excited to leverage the public financial markets to fund expansion and further accelerate our strategy to deliver consumers a convenient and affordable option when purchasing prescription drugs in the United States."
INGEN TECHNOLOGIES INCORPORATED (OTC: IGNT) "Up 107.69% on Friday" Detailed Quote: http://www.otcpicks.com/quotes/IGNT.php Ingen Technologies, Inc. is the leading world manufacturer of gravity-independent in-line oxygen flow meter products and services related to pulmonary and respiratory therapeutic hospital and home oxygen therapy. The company has adopted quality improvement (QI) initiatives throughout all areas of operations. Ingen Technologies is registered with the Food & Drug Administration, and licensed in good standing with the Department of Health Services. Headquartered in Yucaipa, California, the company distributes its respiratory products in North America, Asia and European Communities, and its operations provide sales, logistics, billing and collections. Supported by corporate functions such as Finance, Information Services, Human Resources, Legal and Contract Services, Ingen Technologies division and regional business units are able to respond quickly to customer and patient needs.
IGNT News: May 15 - Ingen Files Quarterly Financials and Moves Forward With Great Promise Ingen Technologies, Inc. (OTC: IGNT), a leading Global Medical Device manufacturer focused in the $ 4 Billion U.S. Respiratory Market for the growing aging and emerging markets for Home (DME), Hospital and Aviation Industries, announced that it complied with the reporting obligations of FINRA and the PINK OTC Markets. The company was recently notified by PINK OTC Markets that after a review of the information posted to pinksheets.com, they have determined that the company has met the requirements for the Current Information tier for the period ending 02/28/2009. Ingen Technologies has seen a slight increase in their Oxyview sales and distribution interest during the past two quarters, including several major events occurring with various OEM partnership negotiations that will be announced in the near future. “We are discussing OEM partnerships with two large global distributors that have a strong foot-hold in the pharmaceutical and respiratory home medical equipment arena,” stated Thomas Neavitt, Chief Financial Officer of Ingen. The company has recently received issuance from China for the Oxyview patent and intellectual property rights in that country. With patents pending in the entire European Community and Japan, the company foresees no problems preventing their issuance as scheduled later this year. ABOUT OXYVIEW Oxyview is a proprietary medical device with US issued patents that stands alone in an increasing patient home oxygen therapy market while there are 23 million patients diagnosed with chronic obstructive pulmonary disease (COPD) in the United States, according to the World Health Organization, and another 12 million patients that are undiagnosed in the US. COPD is the fifth leading cause of death in the US and there are 600 million COPD patients worldwide where in most cases, COPD is either the first or second leading cause of death in other countries. The majority of COPD patients require continued home oxygen therapy, which includes all of the required equipment supplied by the home (DME) provider. With the new regulations for oxygen reimbursement in the US, the home (DME) providers need to cut costs to stay in business. Oxyview provides a substantial savings as a result of decreasing the number of service calls for the home (DME) provider. Oxyview is a pneumatic metering device that displays oxygen flow near the patient. The Oxyview flow meter easily and quickly installs on to the oxygen tubing nearest the patient where oxygen flow matters the most. Without the Oxyview, patients cannot confirm oxygen flow, and as a result there is an increase in anxiety and the patient calls the home (DME) provider with concerns. Oxyview also allows the home (DME) provider to trouble-shoot other equipment problems over the telephone which eliminates an on-site visit with the patient. More important, the Oxyview provides the patient with more assurance that they are receiving adequate and prescribed oxygen flow. The Oxyview costs less than a single service call.
About OTCPicks.com
OTCPicks.com is fast becoming the premier Internet destination for investors seeking information on smallcap and microcap companies. The web site features companies in Profile Campaigns, Executive Interviews and Research Reports authored by our financial writers. We publish our Daily Market Movers Digest Newsletter to opt-in investor members. OTCPicks.com presents the latest information for the discerning small cap and microcap investor. The site features informative articles on microcap investing, the top penny stock picks, and a wealth of small cap research on vertical markets. To feature a company on OTCPicks.com, please contact our publisher, Brian Dean at 972-546-3740, or via email at publisher@otcpicks.com.
Forward-Looking Statement:
This press release includes "forward-looking statements" within the meaning of the federal securities laws, commonly identified by such terms as "believes," "looking ahead," "anticipates," "estimates" and other terms with similar meaning. Although the Company believes that the assumptions upon which its forward-looking statements are based are reasonable, it can give no assurance that these assumptions will prove to be correct. Important factors that could cause actual results to differ materially from the Company's projections and expectations are disclosed in the Company's filings with the Securities and Exchange Commission. All forward-looking statements in this press release are expressly qualified by such cautionary statements and by reference to the underlying assumptions. Disclosure: OTCPicks.com has not been compensated by any of the companies covered in this release. OTCPicks.com is not a registered investment advisers or broker/dealer. OTCPicks.com makes no recommendation that the purchase of securities of companies profiled in this website is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market their securities, investing in such securities is highly speculative and carries a high degree of risk.
